- Home
- RVT vs GERN Comparison
RVT vs GERN Comparison
Compare RVT & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RVT
- GERN
- Stock Information
- Founded
- RVT 1986
- GERN 1990
- Country
- RVT United States
- GERN United States
- Employees
- RVT N/A
- GERN N/A
- Industry
- RVT Trusts Except Educational Religious and Charitable
- GERN Biotechnology: Pharmaceutical Preparations
- Sector
- RVT Finance
- GERN Health Care
- Exchange
- RVT Nasdaq
- GERN Nasdaq
- Market Cap
- RVT 1.9B
- GERN 1.5B
- IPO Year
- RVT N/A
- GERN 1996
- Fundamental
- Price
- RVT $14.51
- GERN $1.59
- Analyst Decision
- RVT
- GERN Buy
- Analyst Count
- RVT 0
- GERN 11
- Target Price
- RVT N/A
- GERN $5.80
- AVG Volume (30 Days)
- RVT 243.4K
- GERN 15.2M
- Earning Date
- RVT 01-01-0001
- GERN 05-07-2025
- Dividend Yield
- RVT 7.32%
- GERN N/A
- EPS Growth
- RVT N/A
- GERN N/A
- EPS
- RVT 2.95
- GERN N/A
- Revenue
- RVT N/A
- GERN $76,994,000.00
- Revenue This Year
- RVT N/A
- GERN $208.83
- Revenue Next Year
- RVT N/A
- GERN $57.49
- P/E Ratio
- RVT $4.98
- GERN N/A
- Revenue Growth
- RVT N/A
- GERN 32386.92
- 52 Week Low
- RVT $11.85
- GERN $1.45
- 52 Week High
- RVT $14.93
- GERN $5.34
- Technical
- Relative Strength Index (RSI)
- RVT 43.70
- GERN 36.39
- Support Level
- RVT $14.03
- GERN $1.63
- Resistance Level
- RVT $14.65
- GERN $1.89
- Average True Range (ATR)
- RVT 0.25
- GERN 0.11
- MACD
- RVT 0.05
- GERN 0.02
- Stochastic Oscillator
- RVT 58.54
- GERN 31.82
About RVT Royce Value Trust Inc.
Royce Value Trust Inc is a diversified closed-end investment company. It invests in diversified sectors including consumer discretionary, consumer staples, healthcare, financial, IT, telecommunications, and materials. The company's portfolio includes common stocks, preferred stocks, corporate bonds, and repurchase agreements.
About GERN Geron Corporation
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.